Cinque B, Di Marzio L, Della Riccia D N, Bizzini F, Giuliani M, Fanini D, De Simone C, Cifone M G
Department of Experimental Medicine, University of L'Aquila, Italy.
Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):775-86. doi: 10.1177/039463200601900407.
Current management of atopic dermatitis is mainly directed to the reduction of cutaneous inflammation. Since patients with atopic dermatitis show abnormalities in immunoregulation, a therapy aimed to adjust their immune function could represent an alternative approach, particularly in the severe form of the disease. Indeed, T-lymphocytes constitute a large population of cellular infiltrate in atopic/allergic inflammation and a dysregulated T-cell induced keratinocyte apoptosis appears to be an important pathogenetic factor of the eczematous disease. In recent years, attention has been focused on the interaction between host and probiotics which may have anti-inflammatory properties and immunomodulatory activities. The aim of the present work is to investigate the effect of a selected probiotic extract, the Bifidobacterium infantis extract, on a human keratinocyte cell line (HaCaT) abnormal apoptosis induced by activated-T-lymphocyte. An in vitro model of atopic dermatitis was used to assess the ability of the probiotic extract to protect HaCaT from apoptosis induced by soluble factors (IFN-gamma and CD95 ligand) released by human T-lymphocytes in vitro activated with anti-CD3/CD28 mAbs or Phytohemoagglutinin. Evidence is given that the bacterial extract treatment was able to totally prevent T lymphocyte-induced HaCaT cell apoptosis in vitro. The mechanism underlying this inhibitory effect has been suggested to depend on the ability of the bacterial extract to significantly reduce anti-CD3/CD28 mAbs and mitogen-induced T-cell proliferation, IFN-gamma generation and CD95 ligand release. These preliminary results may represent an experimental basis for a potential therapeutic approach mainly targeting the skin disorders-associated immune abnormalities.
特应性皮炎的当前治疗主要针对减轻皮肤炎症。由于特应性皮炎患者表现出免疫调节异常，旨在调节其免疫功能的疗法可能是一种替代方法，尤其是对于该疾病的严重形式。事实上，T淋巴细胞在特应性/过敏性炎症中构成大量细胞浸润，而失调的T细胞诱导的角质形成细胞凋亡似乎是湿疹性疾病的一个重要致病因素。近年来，人们的注意力集中在宿主与益生菌之间的相互作用上，益生菌可能具有抗炎特性和免疫调节活性。本研究的目的是调查一种选定的益生菌提取物，即婴儿双歧杆菌提取物，对活化T淋巴细胞诱导的人角质形成细胞系（HaCaT）异常凋亡的影响。使用特应性皮炎的体外模型来评估益生菌提取物保护HaCaT免受体外用人抗CD3/CD28单克隆抗体或植物血凝素激活的T淋巴细胞释放的可溶性因子（IFN-γ和CD95配体）诱导的凋亡的能力。有证据表明，细菌提取物处理能够在体外完全预防T淋巴细胞诱导的HaCaT细胞凋亡。这种抑制作用的潜在机制被认为取决于细菌提取物显著降低抗CD3/CD28单克隆抗体和丝裂原诱导的T细胞增殖、IFN-γ生成和CD95配体释放的能力。这些初步结果可能为主要针对与皮肤疾病相关的免疫异常的潜在治疗方法提供实验基础。
